| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 8.227 | 86 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 9.949 | 94 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 11.190 | 1.889 | 2.281 | 60.490 | 1.239 | 1.420 | 1.647 | 345 | 94 | 477 |
| Gross Profit/Loss - EUR | -1.241 | -1.795 | -2.281 | -60.490 | -1.239 | -1.420 | -1.647 | -345 | -94 | -477 |
| Net Profit/Loss - EUR | -1.558 | -1.801 | -2.281 | -60.490 | -1.239 | -1.420 | -1.647 | -345 | -94 | -477 |
| Employees | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Novopharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 58.424 | 61.259 | 62.570 | 417 | 1.560 | 1.151 | 1.070 | 730 | 1.645 | 1.348 |
| Inventories | 41.033 | 43.492 | 44.873 | -14.448 | 40 | -13.897 | -13.591 | -13.633 | -13.590 | 39 |
| Receivables | 16.572 | 17.066 | 17.421 | 14.856 | 543 | 14.552 | 14.230 | 14.276 | 14.230 | 598 |
| Cash | 819 | 701 | 276 | 8 | 977 | 496 | 431 | 87 | 1.004 | 711 |
| Shareholders Funds | -3.582 | -5.346 | -7.537 | -67.888 | -67.812 | -67.946 | -68.086 | -68.643 | -68.528 | -68.622 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 62.006 | 66.605 | 70.107 | 68.305 | 69.372 | 69.098 | 69.156 | 69.373 | 70.173 | 69.971 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2042 - 2042" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Novopharma Srl